Annovis Bio, Inc. (ANVS)

Annovis Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	10.55	5.75	28.38	45.69	8.07
Cash & Short-Term Investments	10.55	5.75	28.38	45.69	8.07
Cash Growth	83.36%	-79.72%	-37.89%	465.79%	434488.70%
Prepaid Expenses	0.37	0.04	0.1	0.07	0.04
Other Current Assets	3.01	4.41	7.54	0.24	0.01
Total Current Assets	13.93	10.21	36.02	46	8.12
Total Assets	13.93	10.21	36.02	46	8.12
Accounts Payable	2.31	1.29	3.96	0.69	0.34
Accrued Expenses	1.58	2.99	3.74	0.82	0.24
Total Current Liabilities	3.88	4.28	7.7	1.51	0.58
Other Long-Term Liabilities	0.74	13.68	-	-	-
Total Liabilities	4.62	17.96	7.7	1.51	0.58
Common Stock	0	0	0	0	0
Additional Paid-In Capital	144.16	102.51	82.38	73.22	21.78
Retained Earnings	-134.85	-110.26	-54.05	-28.73	-14.24
Total Common Equity	9.31	-7.75	28.32	44.49	7.54
Shareholders' Equity	9.31	-7.75	28.32	44.49	7.54
Total Liabilities & Equity	13.93	10.21	36.02	46	8.12
Net Cash (Debt)	10.55	5.75	28.38	45.69	8.07
Net Cash Growth	83.36%	-79.72%	-37.89%	465.79%	-
Net Cash Per Share	0.86	0.64	3.48	5.99	1.28
Filing Date Shares Outstanding	19.49	11.01	8.22	8.16	6.95
Total Common Shares Outstanding	14.14	10.52	8.16	8.1	6.89
Working Capital	10.04	5.93	28.32	44.49	7.54
Book Value Per Share	0.66	-0.74	3.47	5.49	1.09
Tangible Book Value	9.31	-7.75	28.32	44.49	7.54
Tangible Book Value Per Share	0.66	-0.74	3.47	5.49	1.09

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q